Avita Therapeutics with ticker code (RCEL) have now 5 analysts covering the stock. The analyst consensus points to a rating of ‘Strong_Buy’. The target price ranges between 60 and 35 and has a mean target at 45.2. Given that the stocks previous close was at 17.55 this is indicating there is a potential upside of 157.5%. The 50 day MA is 21.07 and the 200 moving average now moves to 24.52. The market capitalisation for the company is $380m. Company Website: http://www.avitamedical.com
AVITA Medical Inc. operates as a commercial-stage regenerative tissue company in the United States, Australia, and the United Kingdom. It offers regenerative products to address unmet medical needs in burn injuries, trauma injuries, chronic wounds, and dermatological and aesthetics indications, including vitiligo. The company’s patented and proprietary platform technology provides treatment solutions derived from the regenerative properties of a patient’s own skin. Its lead product is RECELL System, a device that enables healthcare professionals to produce a suspension of Spray-On Skin cells using a small sample of the patient’s own skin for use in the treatment of acute thermal burns in patients eighteen years and older. The company has a research collaboration with the University of Colorado School of Medicine to establish and explore development of a spray-on treatment for patients with epidermolysis bullosa; and a research collaboration with Houston Methodist Research Institute to explore novel approaches for skin rejuvenation. The company was formerly known as AVITA Therapeutics and changed its name to AVITA Medical Inc. in December 2020. AVITA Medical Inc. is based in Valencia, California.